Riset dan Pengabdian Masyarakat
Do Research Sosial Service and Innovation
Publikasi Scopus Covid-19 Per 14 Agustus 2024 (559 artikel)
Publikasi Scopus Covid-19 Per 14 Agustus 2024 (559 artikel)
Adriana, Deasy Natalia (57221635177); Sugihartono, Titong (57194156387); Nusi, Iswan Abbas (56543515200); Setiawan, Poernomo Boedi (6507682592); Purbayu, Herry (57194162048); Maimunah, Ummi (56543645400); Kholili, Ulfa (57209663659); Widodo, Budi (57211323878); Thamrin, Husin (57204648560); Vidyani, Amie (57211316314); Maulahela, Hasan (57189612709); Yamaoka, Yoshio (55183784100); Miftahussurur, Muhammad (56323903000)
Role of fecal calprotectin as a hypoxic intestinal damage biomarker in COVID-19 patients
2022
Gut Pathogens
14
1
34
8
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85135693815&doi=10.1186%2fs13099-022-00507-y&partnerID=40&md5=9b1ac833cb5cd5db1083d5b4a48df12e
Department of Internal Medicine, Faculty of Medicine, Soetomo Teaching Hospital, Universitas Airlangga, Dr, Surabaya, 60286, Indonesia; Gastroenterology and Hepatology Division, Department of Internal Medicine, Faculty of Medicine, Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya, 60286, Indonesia; Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Helicobacter Pylori and Microbiota Study Group, Institute of Tropical Disease, Universitas Airlangga, Surabaya, 60115, Indonesia; Department of Environmental and Preventive Medicine, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Oita, Yufu, 879-5593, Japan; Department of Medicine, Gastroenterology and Hepatology Section, Baylor College of Medicine, Houston, TX, United States
Background: Gastrointestinal manifestations of coronavirus disease 2019 (COVID-19) appear to be substantial. Fecal calprotectin is a promising biomarker in COVID-19 associated gastrointestinal inflammation; however, its role in the severity of COVID-19 remains limited. We conducted a study to analyze the relationship between the severity of COVID-19 and hypoxic intestinal damage. Methods: We assessed the severity of 44 hospitalized COVID-19 pneumonia patients based on the PaO2/FiO2 (P/F) ratio. Inflammatory markers were measured from blood samples, and fecal calprotectin was obtained from stool samples. Results: Median levels of fecal calprotectin in COVID-19 patients involved in this study (n = 44) were found to be markedly elevated along with the severity of hypoxemia, as seen in the non-acute respiratory distress syndrome (ARDS) group 21.4 µg/g (5.2–120.9), mild ARDS 54.30 µg/g (5.2–1393.7), moderate ARDS 169.6 µg/g (43.4–640.5), and severe ARDS 451.6 µg/g (364.5–538.6). We also found significant differences in fecal calprotectin levels based on the severity of ARDS (P < 0.001), and although the patients were divided into ARDS and non-ARDS groups (P < 0.001). Furthermore, we found a strong negative correlation between the P/F ratio and fecal calprotectin levels (r = − 0.697, P < 0.001). Conclusion: Our findings support the potential role of fecal calprotectin as a biomarker of intestinal inflammation in COVID-19 as a consequence of hypoxic intestinal damage and as suggested by the reduced P/F ratio. © 2022, The Author(s).
biological marker; calgranulin; adult; adult respiratory distress syndrome; Article; clinical article; clinical feature; coronavirus disease 2019; disease severity; feces analysis; female; Horowitz index; human; hypoxemia; intestine injury; male; observational study; risk factor
Universitas Airlangga, UNAIR; , (21H00346)
This research is funded by Research and Community Services Institute, Universitas Airlangga.
BioMed Central Ltd
17574749
Article
Q1